1. Home
  2. BJ vs ABVX Comparison

BJ vs ABVX Comparison

Compare BJ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BJ's Wholesale Club Holdings Inc.

BJ

BJ's Wholesale Club Holdings Inc.

HOLD

Current Price

$96.70

Market Cap

12.9B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$109.76

Market Cap

10.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BJ
ABVX
Founded
1984
2013
Country
United States
France
Employees
N/A
67
Industry
Department/Specialty Retail Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
10.5B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BJ
ABVX
Price
$96.70
$109.76
Analyst Decision
Buy
Buy
Analyst Count
16
12
Target Price
$109.40
$128.42
AVG Volume (30 Days)
1.7M
714.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
3.09
N/A
EPS
3.42
N/A
Revenue
$20,501,804,000.00
N/A
Revenue This Year
$9.10
N/A
Revenue Next Year
$6.71
$0.22
P/E Ratio
$28.83
N/A
Revenue Growth
2.67
N/A
52 Week Low
$86.68
$4.77
52 Week High
$121.10
$148.83

Technical Indicators

Market Signals
Indicator
BJ
ABVX
Relative Strength Index (RSI) 47.05 38.48
Support Level $95.12 $107.99
Resistance Level $99.52 $131.27
Average True Range (ATR) 3.47 5.11
MACD -0.32 -1.73
Stochastic Oscillator 36.11 14.40

Price Performance

Historical Comparison
BJ
ABVX

About BJ BJ's Wholesale Club Holdings Inc.

BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 250 clubs and a growing domestic presence across 21 states. In fiscal 2024, the company generated over $20 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (71% of sales), general merchandise (11%), and gasoline (18%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: